Enzo Biochem PE Ratio 2010-2022 | ENZ

Current and historical p/e ratio for Enzo Biochem (ENZ) from 2010 to 2022. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Enzo Biochem PE ratio as of September 23, 2022 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Enzo Biochem PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2022-09-26 2.13 0.00
2022-04-30 2.55 $-0.13 0.00
2022-01-31 3.22 $0.01 322.00
2021-10-31 3.44 $0.11 31.27
2021-07-31 3.26 $0.17 19.18
2021-04-30 3.07 $0.03 102.33
2021-01-31 2.82 $-0.22 0.00
2020-10-31 1.82 $-0.43 0.00
2020-07-31 2.38 $-0.60 0.00
2020-04-30 3.02 $-0.64 0.00
2020-01-31 2.51 $0.04 62.75
2019-10-31 3.16 $0.02 158.00
2019-07-31 3.91 $0.05 78.20
2019-04-30 3.47 $0.04 86.75
2019-01-31 3.76 $-0.49 0.00
2018-10-31 3.32 $-0.33 0.00
2018-07-31 4.42 $-0.21 0.00
2018-04-30 6.00 $-0.09 0.00
2018-01-31 7.36 $-0.03 0.00
2017-10-31 9.85 $-0.03 0.00
2017-07-31 10.85 $-0.05 0.00
2017-04-30 8.80 $0.72 12.22
2017-01-31 6.68 $0.67 9.97
2016-10-31 6.10 $0.84 7.26
2016-07-31 6.97 $0.97 7.19
2016-04-30 4.98 $0.38 13.11
2016-01-31 4.74 $0.37 12.81
2015-10-31 3.72 $0.13 28.62
2015-07-31 3.00 $-0.05 0.00
2015-04-30 2.80 $-0.30 0.00
2015-01-31 3.15 $-0.25 0.00
2014-10-31 5.22 $-0.25 0.00
2014-07-31 4.80 $-0.24 0.00
2014-04-30 4.20 $-0.25 0.00
2014-01-31 2.81 $-0.39 0.00
2013-10-31 2.49 $-0.44 0.00
2013-07-31 2.18 $-0.46 0.00
2013-04-30 2.24 $-1.07 0.00
2013-01-31 2.89 $-1.01 0.00
2012-10-31 2.00 $-0.98 0.00
2012-07-31 1.50 $-1.01 0.00
2012-04-30 2.74 $-0.43 0.00
2012-01-31 2.55 $-0.39 0.00
2011-10-31 2.86 $-0.43 0.00
2011-07-31 3.84 $-0.34 0.00
2011-04-30 3.99 $-0.38 0.00
2011-01-31 4.96 $-0.45 0.00
2010-10-31 4.31 $-0.57 0.00
2010-07-31 4.60 $-0.59 0.00
2010-04-30 5.97 $-0.58 0.00
2010-01-31 4.74 $-0.57 0.00
2009-10-31 5.51 $-0.50 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.105B $0.118B
Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. The business activities of the company are performed by one of the company's three wholly-owned subsidiaries--Enzo Diagnostics, Inc., Enzo Therapeutics, Inc., and Enzo Clinical Labs, Inc. The primary focus of the company's research is the development of products based on two technology platforms -- genetic modulation and immune modulation.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $150.984B 9.16
GSK (GSK) United Kingdom $59.709B 7.17
Bio-Rad Laboratories (BIO.B) United States $12.433B 27.47
Biohaven Pharmaceutical Holding (BHVN) United States $10.873B 0.00
QIAGEN (QGEN) Netherlands $9.383B 15.71
Ginkgo Bioworks Holdings (DNA) United States $4.998B 0.00
Arcus Biosciences (RCUS) United States $1.819B 35.51
Myovant Sciences (MYOV) United Kingdom $1.614B 0.00
Emergent Biosolutions (EBS) United States $1.040B 6.03
ADC Therapeutics SA (ADCT) Switzerland $0.376B 0.00
Zymeworks (ZYME) Canada $0.305B 0.00
Gelesis Holdings (GLS) United States $0.081B 0.00
SQZ Biotechnologies (SQZ) United States $0.068B 0.00
Ambrx Biopharma (AMAM) United States $0.041B 0.00